NCT06070857View on ClinicalTrials.gov

Study of the Safety, Tolerability, and Pharmacokinetics of LV232 Capsules in Chinese Healthy Volunteers

PHASE1RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 5, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Healthy Subjects
Interventions
DRUG

LV232

Drug: LV232 1mg,2mg,4mg,8mg,15mg,25mg,40mg,60mg,90mg and 120mg

DRUG

Placebo

Placebo:1mg,2mg,4mg,8mg,15mg,25mg,40mg,60mg,90mg and 120mg

Trial Locations (1)

201900

RECRUITING

Shanghai Xuhui Central Hospital, Shanghai

All Listed Sponsors
lead

Vigonvita Life Sciences

INDUSTRY